Study links gut bacterial compound ImP to increased Alzheimer's risk

Researchers have identified a gut-produced molecule called imidazole propionate (ImP) that may accelerate cognitive decline and increase the accumulation of proteins associated with Alzheimer's disease.

A study published in Nature Communications suggests that ImP, a compound generated by certain bacteria in the digestive system, may contribute to brain changes involved in dementia. According to reports from ScienceDaily and Health & Medicine News, this molecule can enter the bloodstream and travel to the brain, where it has been observed to affect protein levels.

Experiments conducted on mice revealed that when ImP reaches the brain, it increases the accumulation of tau and abnormal beta amyloid proteins. University of Wisconsin-Madison professor Federico Rey noted that this process eventually leads to the death of neurons, which is a primary characteristic of Alzheimer's disease in humans.

The research team also analyzed blood samples from nearly 1,200 participants across studies at the Wisconsin Alzheimer's Disease Research Center and the Wisconsin Registry for Alzheimer's Prevention. They found that individuals with higher concentrations of ImP in their blood were significantly more likely to exhibit biological markers linked to impaired neuron function and abnormal protein levels.

While ImP-producing bacteria are common in many people, their abundance varies. Professor Rey explained that even if these microbes are not highly abundant, they can still have a notable impact on the host. ScienceDaily noted that previous research has already linked this specific compound to other health issues, including coronary artery disease and type 2 diabetes.

Background

Nearly a decade ago, University of Wisconsin-Madison professors Barbara Bendlin and Federico Rey discovered that the intestinal microorganisms of people with Alzheimer's differ from those of healthy individuals, leading to ongoing research into how gut health affects the brain.